4/25
04:30 pm
rare
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Neutral
Report
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
4/24
01:38 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
4/22
08:09 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
4/19
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/16
01:19 pm
rare
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study [Yahoo! Finance]
Medium
Report
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study [Yahoo! Finance]
4/16
10:55 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
4/15
07:10 am
rare
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 [Yahoo! Finance]
Medium
Report
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 [Yahoo! Finance]
4/15
07:00 am
rare
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Medium
Report
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
4/12
04:33 pm
rare
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome [Yahoo! Finance]
Medium
Report
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome [Yahoo! Finance]
4/12
04:22 pm
rare
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Medium
Report
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
4/12
08:14 am
rare
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
4/12
08:00 am
rare
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Medium
Report
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
4/5
10:26 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
3/22
04:00 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/18
02:51 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $88.00 to $92.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $88.00 to $92.00. They now have an "overweight" rating on the stock.
2/27
04:30 pm
rare
Ultragenyx to Participate at Investor Conferences in March
Low
Report
Ultragenyx to Participate at Investor Conferences in March
2/27
02:17 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $84.00 to $88.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $84.00 to $88.00. They now have an "overweight" rating on the stock.
2/27
10:17 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
2/23
04:05 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/21
09:22 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $110.00 to $111.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $110.00 to $111.00. They now have a "buy" rating on the stock.
2/16
10:53 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/16
09:21 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Wedbush from $47.00 to $48.00. They now have a "neutral" rating on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Wedbush from $47.00 to $48.00. They now have a "neutral" rating on the stock.
2/16
09:06 am
rare
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat [Yahoo! Finance]
Low
Report
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat [Yahoo! Finance]
2/15
08:02 pm
rare
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics [Yahoo! Finance]
Medium
Report
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key Metrics [Yahoo! Finance]
2/15
04:14 pm
rare
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update [Yahoo! Finance]
Low
Report
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update [Yahoo! Finance]